Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

OMER – Omeros Corporation

Float Short %

19.66

Margin Of Safety %

Put/Call OI Ratio

0.6

EPS Next Q Diff

0.02

EPS Last/This Y

0.68

EPS This/Next Y

1.85

Price

4.4

Target Price

22.5

Analyst Recom

2

Performance Q

36.65

Relative Volume

0.81

Beta

2.36

Ticker: OMER




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25OMER3.840.590.2936764
2025-07-28OMER4.160.567.9739824
2025-07-29OMER3.970.700.6246309
2025-07-30OMER3.870.700.1348018
2025-07-31OMER3.860.690.0748552
2025-08-01OMER3.60.670.2549676
2025-08-04OMER3.70.640.0651202
2025-08-05OMER4.030.630.3152007
2025-08-06OMER3.860.630.0152283
2025-08-07OMER3.770.610.0553634
2025-08-08OMER4.050.591.5354646
2025-08-11OMER4.140.590.3555051
2025-08-12OMER4.180.590.3655312
2025-08-13OMER4.260.590.2555828
2025-08-14OMER4.110.590.1356255
2025-08-15OMER4.410.590.0356572
2025-08-18OMER4.220.750.5843538
2025-08-19OMER4.360.760.0344148
2025-08-20OMER4.180.610.0750970
2025-08-21OMER4.470.610.0351202
2025-08-22OMER4.40.600.1751537
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25OMER3.8357.4- -2.02
2025-07-28OMER4.1253.4- -2.02
2025-07-29OMER3.9753.4- -2.02
2025-07-30OMER3.8553.4- -2.02
2025-07-31OMER3.8753.4- -2.02
2025-08-01OMER3.6153.4- -2.02
2025-08-04OMER3.7053.4- -2.02
2025-08-05OMER4.0253.4- -2.02
2025-08-06OMER3.8553.4- -2.02
2025-08-07OMER3.7853.4- -2.02
2025-08-08OMER4.0653.4- -2.08
2025-08-11OMER4.1451.3- -2.08
2025-08-12OMER4.1851.3- -2.08
2025-08-13OMER4.2751.3- -2.08
2025-08-14OMER4.1151.3- -2.08
2025-08-15OMER4.4151.3- -2.08
2025-08-18OMER4.2251.3- -2.08
2025-08-19OMER4.3651.3- -2.08
2025-08-20OMER4.1951.3- -2.08
2025-08-21OMER4.4851.3- -2.08
2025-08-22OMER4.4025.4- -2.02
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25OMER0.002.9724.29
2025-07-28OMER0.002.7924.29
2025-07-29OMER0.002.7924.29
2025-07-30OMER0.002.7921.20
2025-07-31OMER0.002.7921.20
2025-08-01OMER0.002.7921.20
2025-08-04OMER0.002.7621.20
2025-08-05OMER0.002.7621.20
2025-08-06OMER0.002.7621.20
2025-08-07OMER0.002.7621.20
2025-08-08OMER0.002.7621.20
2025-08-11OMER0.003.5021.20
2025-08-12OMER0.003.5019.93
2025-08-13OMER0.003.5019.93
2025-08-14OMER0.003.5019.93
2025-08-15OMER0.003.5019.93
2025-08-18OMER0.003.4119.66
2025-08-19OMER0.003.4119.66
2025-08-20OMER0.003.4119.66
2025-08-21OMER0.003.4119.66
2025-08-22OMER0.003.4119.66
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.53

Avg. EPS Est. Current Quarter

-0.48

Avg. EPS Est. Next Quarter

-0.52

Insider Transactions

Institutional Transactions

3.41

Beta

2.36

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

35

Growth Score

20

Sentiment Score

62

Actual DrawDown %

81.6

Max Drawdown 5-Year %

-95.4

Target Price

22.5

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

-2.11

Average EPS Est. Cur. Y​

-2.02

EPS Next Y. (Est.)

-0.17

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.81

Return on Equity vs Sector %

28.9

Return on Equity vs Industry %

41.8

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

-0.03

EBIT Estimation

Omeros Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 202
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
stock quote shares OMER – Omeros Corporation Stock Price stock today
news today OMER – Omeros Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch OMER – Omeros Corporation yahoo finance google finance
stock history OMER – Omeros Corporation invest stock market
stock prices OMER premarket after hours
ticker OMER fair value insiders trading